With shares of Wal-Mart (NYSE:WMT) trading around $80, is WMT an OUTPERFORM, WAIT AND SEE, or STAY AWAY? Let�� analyze the stock with the relevant sections of our CHEAT SHEET investing framework:
T = Trends for a Stock�� MovementWal-Mart operates retail stores in various formats around the world. The company aims to price items at the lowest price every day. Wal-Mart operates in three business segments: the Walmart U.S. segment, the Walmart international segment, and the Sam�� Club segment. It manages retail stores, restaurants, discount stores, supermarkets, super centers, hypermarkets, warehouse clubs, apparel stores, Sam�� Clubs, neighborhood markets, and other small formats, as well as Walmart.com and SamsClub.com. Through its retail channels, Wal-Mart is able to provide a variety of products and services at affordable prices to consumers and companies worldwide.
Wal-Mart executives are feeling the heat from an investigation by the U.S. Department of Justice over possible violations of the Foreign Corrupt Policies Act. Reuters reports that Wal-Mart is paying for lawyers for as many as 30 executives targeted by the DoJ over suspicion of bribery and other misconduct in Mexico, Brazil, China, and India.
Top Regional Bank Stocks To Buy For 2015: Synthesis Energy Systems Inc.(SYMX)
Synthesis Energy Systems, Inc., a global energy and gasification technology company, provides products and solutions to the energy and chemical industries. It offers technology and equipment in regions, where low rank coals and biomass feed stocks can be converted into high value products through its proprietary U-GAS fluidized bed gasification technology. The company licenses its U-GAS technology rights to third parties and delivers an engineered technology package, as well as provides proprietary equipment components to customers, who have contracted to own and operate projects. It has a joint venture agreement with Shandong Hai Hua Coal and Chemical Company Ltd. for developing, constructing, and operating a syngas production plant utilizing the U-GAS technology in Zao Zhuang City, China; and for producing and selling syngas, and various byproducts of the plant, including ash and elemental sulphur. The syngas can be used as a fuel gas in industrial applications, or can b e used to produce power, synthetic natural gas, methanol, dimethyl ether, glycol, ammonia, direct reduction iron, and synthetic gasoline, as well as other transportation fuels, steam, sulphur, carbon dioxide, or ash. Synthesis Energy Systems, Inc. was founded in 2003 and is headquartered in Houston, Texas.
Advisors' Opinion:- [By Roberto Pedone]
One under-$10 specialty chemicals player that's starting to move within range of triggering a major breakout trade is Synthesis Energy Systems (SYMX), which provides various proprietary gasification technology systems and solutions to the energy and chemical industries worldwide. This stock is off to a red hot start so far in 2014, with shares up a whopping 191%.
If you glance at the chart for Synthesis Energy Systems, you'll see that this stock has been uptrending over the last month and change, with shares moving higher from its low of $1.39 to its recent high of $1.85 a share. During that uptrend, shares of SYMX have been making mostly higher lows and higher highs, which is bullish technical price action. That move has started to push shares of SYMX within range of triggering a major breakout trade above some key near-term overhead resistance levels.
Traders should now look for long-biased trades in SYMX if it manages to break out above some near-term overhead resistance levels at $1.85 to $1.86 a share and then once it takes out more key overhead resistance levels at $1.93 to $2 and $2.09 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 594,782 shares. If that breakout gets underway soon, then SYMX will set up to re-test or possibly take out its next major overhead resistance levels at $2.44 to its 52-week high at $2.49 a share. Any high-volume move above those levels will then give SYMX a chance to tag $3 to $3.50 a share.
Traders can look to buy SYMX off weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at $1.60 to $1.55 a share. One can also buy SYMX off strength once it starts to clear those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
- [By Lisa Levin]
Synthesis Energy Systems (NASDAQ: SYMX) shares jumped 26.01% to $2.18 on the receipt of a 20-year business license for China Clean Coal Gasification joint venture
Top 5 Supermarket Stocks To Own Right Now: Madison Square Garden Inc.(MSG)
The Madison Square Garden Company, together with its subsidiaries, operates in the sports, entertainment, and media businesses primarily in the United States. The company operates in three segments: MSG Media, MSG Entertainment, and MSG Sports. The MSG Media segment produces and develops content for various distribution platforms, including content originating from the company?s venues. It consists of the MSG Networks and the Fuse Networks, which offer sports and musical content. This segment also manages interactive businesses that comprise a range of targeted websites; and wireless, video on demand, and digital platforms. The MSG Entertainment segment creates, produces, and/or presents various live productions, as well as presents or hosts other live entertainment events, such as concerts, family shows, special events, and theatrical productions. The MSG Sports segment owns and operates sports franchises. This segment also owns other sports properties, including the pre sentation of a range of live sporting events, such as professional boxing, college basketball, track and field, and tennis. The company owns the Madison Square Garden complex in New York City, which includes an arena and a theater; and The Chicago Theatre in Chicago. It leases Radio City Music Hall and the Beacon Theatre in New York City. The company is based in New York, New York. As of February 09, 2010, Madison Square Garden, Inc. operates independently of Cablevision Systems Corporation.
Advisors' Opinion:- [By Sue Chang]
Madison Square Garden Co. (MSG) �is forecast to post fiscal first-quarter earnings of 21 cents a share.
- [By Ian Wyatt, Publisher & Chief Investment Strategist, Wyatt Investment Research]
Meanwhile, Mark Boyar, of The Boyar Value Fund, recommends another household name: Madison Square Garden (MSG). He thinks the Dolan family could take the company private.
Top 5 Supermarket Stocks To Own Right Now: GigaMedia Limited (GIGM)
Gigamedia Limited, through its subsidiaries, primarily engages in the operation of online games for online game players in Asia. The company provides a portfolio of online games, including MahJong, a traditional Chinese tile game; MMORPG, an Internet-based computer game; advanced casual games; and card, chance-based, and simple casual games. It also develops and licenses online poker, casino, and sports betting gaming software solutions, as well as offers application services for the online poker and casino markets primarily in the continental European markets. The company has strategic alliances with SoftStar Entertainment Inc., Neostorm Holdings Limited, XLGames Inc., Access China Holding Limited, Gorilla Banana Entertainment Corp., JC Entertainment Corporation, Possibility Space Incorporated, East Gate Media Contents & Technology Fund, and BetClic. GigaMedia Limited was founded in 1997 and is headquartered in Taipei, Taiwan.
Advisors' Opinion:- [By Eric Volkman]
GigaMedia (NASDAQ: GIGM ) results for the company's fiscal Q4 and 2012 have been released. For the quarter, revenue was $4.8 million, down by 34% from the $7.4 million in the same period the previous year. Attributable net loss, however, narrowed considerably to $15.4 million ($0.30 per diluted share) from Q4 2011's shortfall of $51.3 million ($1.01).
Top 5 Supermarket Stocks To Own Right Now: Pernix Therapeutics Holdings Inc (PTX)
Pernix Therapeutics Holdings, Inc. (Pernix), incorporated in November 8, 1996, is a specialty pharmaceutical company focused on the sales, marketing and development of branded and generic pharmaceutical products for pediatric and adult indications in a range of therapeutic areas. It manages a portfolio of branded and generic products and theobromine, a non-codeine, cough suppressant product candidate in development. The Company�� branded products for the pediatrics market include CEDAX, an antibiotic for middle ear infections, NATROBA, a topical treatment for head lice marketed under an exclusive co-promotion agreement with ParaPRO, LLC and a family of prescription treatments for cough and cold (BROVEX, ALDEX and PEDIATEX). It also markets REZYST IM, which is a probiotic blend to promote dietary management. Pernix markets generic products through its wholly owned subsidiary, Macoven Pharmaceuticals, LLC. In January 2013, the Company acquired Cypress Pharmaceuticals, Inc. and Hawthorn Pharmaceuticals, Inc. In March 2013, the Company acquired Somaxon Pharmaceuticals Inc. In September 2013, Pernix Therapeutics Holdings, Inc. completed the sale of certain non-core assets to Breckenridge Pharmaceutical, Inc.
The Company�� customers consist of drug wholesalers, retail drug stores, mass merchandisers and grocery store pharmacies in the United States. It primarily sells products directly to drug wholesalers, which in turn distribute the products to retail drug stores, mass merchandisers and grocery store pharmacies.
ALDEX Line
ALDEX is a line of antihistamines, decongestants and cough suppressants that are indicated for the temporary relief of respiratory allergies, allergic rhinitis and symptoms of the common cold. The Company�� ALDEX product line is marketed in a range of formulations and combinations using different drug-delivery methodologies to target specific segments of the antihistamine, decongestant and cough suppressant markets. Two used decongestants ar! e phenylephrine and pseudoephedrine.
BROVEX Line
The BROVEX line is a line of antihistamine combinations with the active pharmaceutical ingredient (API) brompheniramine maleate, part of the first generation class of antihistamines called alkylamines that are indicated for the temporary relief of sneezing, itchy, watery eyes, itchy nose or throat, and runny nose due to hay fever or other respiratory allergies. Its BROVEX product line is marketed in a range of formulations and combinations to target specific segments of the antihistamine market. The Company completed the conversion of the BROVEX product family to over-the-counter (OTC) monograph from DESI drugs, in April 2011.
CEDAX Line
CEDAX is a third generation oral cephalosporin indicated for the treatment of mild to moderate acute bacterial exacerbations of chronic bronchitis, middle ear infection due to haemophilus influenza or streptococcus pyogenes. The Company sells a range of dosages utilizing both capsule and oral suspension drug delivery methodologies. It also owns a trademark on the name CEDAX in the United States.
NATROBA Line
NATROBA Topical Suspension is a prescription medicine used to treat head lice (pediculosis capitis) in adults and children four years of age and older. NATROBA contains the active ingredient spinosad, which is derived from a naturally occurring soil bacterium.
PEDIATEX Line
As of December 31, 2011, the only product that the Company marketed and sold in its PEDIATEX line is PEDIATEX TD. PEDIATEX TD is an antihistamine/nasal decongestant combination liquid for oral administration. Each 1 milliliter dose contains the API Tripolidine HC1 and Pseudoephedrine HC1. Tripolidine HC1 is a first generation antihistamine in the alkylamine class. Pseudoephedrine, a decongestant, is a sympathomimetic, which acts on alpha-adrenergic receptors in the mucosa of the respiratory tract, producing vasoconstriction and having minimal eff! ect on be! ta-receptors. It therefore functions as an oral nasal decongestant with minimal central nervous system stimulation.
REZYST Line
REZYST IM is a probiotic blend that promotes the dietary management of patients with the distinctive nutritional requirements associated with the gastro-intestinal flora. It is formulated to improve the digestive health of patients by replacing the active cultures altered by diet, stress, and antibiotics.
Product Candidates in Development
Product candidates in development include Theobromine. Theobromine is an alkaloid naturally present in dark chocolate which is an existing human metabolite of caffeine. The Company is working on several other product candidates, which includes a prescription product for the pediatrics market. In March 2012, the Company entered into a product development agreement with a private company for this product.
Advisors' Opinion:- [By Michael Douglass and David Williamson]
Shares of�Pernix Therapeutics� (NASDAQ: PTX ) soared 31% yesterday after the company revealed that it had bought the U.S. rights to�GlaxoSmithKline's (NYSE: GSK ) Treximet (which helps treat migraines in adults) for $250 million upfront (and some potential additional payments later). The importance of this purchase cannot easily be overstate for Pernix -- the company had $85 million in revenue last year, while Treximet on its own brought in $79 million -- and Pernix clearly sees some additional upside potential for the drug, whether it's through a potential indication expansion (to pediatric patients) or through synergies with Pernix's current salesforce.
- [By Jake L'Ecuyer]
Leading and Lagging Sectors
Healthcare stocks gained Wednesday, with Senomyx (NASDAQ: SNMX) leading advancers after the company announced a research agreement with PepsiCo (NYSE: PEP). Among the leading sector stocks, gains came from Pernix Therapeutics Holdings (NASDAQ: PTX), Albany Molecular Research (NASDAQ: AMRI) and Gentiva Health Services (NASDAQ: GTIV).
No comments:
Post a Comment